Correlation Between SAB Biotherapeutics and NuCana PLC

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and NuCana PLC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and NuCana PLC into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and NuCana PLC, you can compare the effects of market volatilities on SAB Biotherapeutics and NuCana PLC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of NuCana PLC. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and NuCana PLC.

Diversification Opportunities for SAB Biotherapeutics and NuCana PLC

-0.58

Correlation Coefficient

SAB Biotherapeutics  NuCana PLC

Excellent diversification

The 3 months correlation between SAB and NuCana is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and NuCana PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NuCana PLC and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with NuCana PLC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NuCana PLC has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and NuCana PLC go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and NuCana PLC

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 0.92 times more return on investment than NuCana PLC. However, SAB Biotherapeutics is 1.09 times less risky than NuCana PLC. It trades about 0.18 of its potential returns per unit of risk. NuCana PLC is currently generating about 0.01 per unit of risk. If you would invest  2.50  in SAB Biotherapeutics on September 13, 2024 and sell it today you would earn a total of  4.50  from holding SAB Biotherapeutics or generate 180.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	88.89%
Values	Daily Returns

SAB Biotherapeutics  vs.  NuCana PLC

SAB Biotherapeutics

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

NuCana PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days NuCana PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat weak basic indicators, NuCana PLC may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with SAB Biotherapeutics and NuCana PLC

The main advantage of trading using opposite SAB Biotherapeutics and NuCana PLC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, NuCana PLC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NuCana PLC will offset losses from the drop in NuCana PLC's long position.

The idea behind SAB Biotherapeutics and NuCana PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.